Yes, there are several cheaper alternatives to Eliquis, though the best option depends on your insurance situation, your medical condition, and how soon you need savings. Eliquis (apixaban) can cost over $500 a month without insurance, making it one of the most expensive commonly prescribed medications in the United States. Generic apixaban is not yet available in the U.S., but a combination of other blood thinners, manufacturer programs, and upcoming price changes can significantly cut your costs.
Generic Apixaban Is Coming, but Not Yet Here
The FDA has given tentative approval to generic versions of apixaban from manufacturers like Sun Pharma, but patent protections on the brand-name drug prevent these generics from reaching the U.S. market until at least late 2026. The key patent doesn’t expire until November 21, 2026, and a secondary patent extends to 2031. Once generics do launch, prices are expected to drop substantially, as typically happens when multiple generic manufacturers compete.
Generic apixaban is already available in other countries. In Canada, a 30-day supply costs roughly $79. In India, it runs about $75 for a month. Some international pharmacy sources list prices as low as $42 for a 30-day supply. Importing prescription drugs from other countries carries legal and safety considerations, but verified international pharmacy programs do exist for U.S. residents looking to lower costs now.
Other Blood Thinners and What They Cost
Eliquis belongs to a class of newer blood thinners called direct oral anticoagulants. The other drugs in this class work through similar mechanisms and are prescribed for many of the same conditions, including preventing strokes in atrial fibrillation and treating blood clots. Their prices vary widely.
- Xarelto (rivaroxaban): Available through discount programs for as low as $50 per month. It’s taken once daily instead of twice, which some people prefer. It carries a slightly higher risk of gastrointestinal bleeding compared to Eliquis.
- Pradaxa (dabigatran): Available for as low as $95 per month through discount pricing. It’s the only newer blood thinner with an established reversal agent that’s been on the market for years, which can matter in emergency bleeding situations.
- Savaysa (edoxaban): Considerably more expensive at around $458 per month and less commonly prescribed, making it a poor choice if cost is your primary concern.
These medications are not identical to Eliquis. They differ in dosing schedules, bleeding risk profiles, and how they interact with kidney function. Switching from Eliquis to another blood thinner is a medical decision, not just a financial one, so your doctor needs to weigh in on which alternatives are appropriate for your specific situation.
Warfarin: The Oldest and Cheapest Option
Warfarin has been available as a generic for decades and costs just a few dollars a month. For pure sticker price, nothing comes close. But warfarin requires regular blood tests to make sure your blood-clotting levels stay in the right range. Most stable patients need testing about once a month, though early in treatment it can be weekly.
These monitoring visits add cost and inconvenience. Warfarin also interacts with a long list of foods (especially leafy greens high in vitamin K) and other medications, requiring more careful dietary consistency. In clinical comparisons, patients on Eliquis had better overall health outcomes for stroke prevention in atrial fibrillation, gaining roughly half a quality-adjusted life-year over warfarin. That gap matters more for some patients than others. If your finances make Eliquis truly unaffordable and other newer options are also out of reach, warfarin remains an effective blood thinner that has been used successfully for decades.
Manufacturer Savings and Copay Cards
Bristol-Myers Squibb offers a copay assistance program that can bring your Eliquis cost down to as little as $10 per month. The catch: you must have commercial (private) insurance with a copay for Eliquis. The program is capped at $2,000 in annual savings. If you’re on Medicare Part D, Medicaid, TRICARE, VA benefits, or any other government insurance program, you’re not eligible.
For people without any insurance, Bristol-Myers Squibb also runs a separate patient assistance program that may provide Eliquis at no cost, though eligibility is based on income.
Medicare Changes Starting in 2025 and 2026
If you’re on Medicare, two major changes are reshaping what you’ll pay. Starting in 2025, the Inflation Reduction Act caps total out-of-pocket drug spending for Medicare Part D enrollees at $2,000 per year across all prescriptions. That cap alone could dramatically reduce costs for anyone currently paying hundreds monthly for Eliquis.
On top of that, Eliquis was one of the first drugs selected for Medicare price negotiation. The negotiated price takes effect in 2026, setting the cost at $231 for a 30-day supply. That’s the price Medicare will pay, and your share will be a fraction of that, subject to your plan’s specific cost-sharing structure and the $2,000 annual cap. For Medicare enrollees who have been paying high out-of-pocket costs, 2026 represents a significant turning point.
How to Find Your Best Option Now
Your cheapest path depends on your insurance type. If you have commercial insurance, the manufacturer copay card can drop your cost to $10 a month immediately. If you’re on Medicare, the new annual spending cap limits your total drug costs to $2,000 starting in 2025, with further savings from negotiated pricing in 2026. If you’re uninsured, GoodRx-style discount cards, patient assistance programs, or verified international pharmacies offer the steepest discounts.
If switching medications is on the table, Xarelto with discount pricing is currently the least expensive of the newer blood thinners, and warfarin remains the cheapest option overall despite its monitoring requirements. Talk to your prescriber about which alternatives are medically appropriate before making a switch based on price alone. Blood thinners are not interchangeable, and the wrong choice for your specific condition could mean inadequate protection against clots or an increased risk of bleeding.